Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma

Stephen W. Erickson, Vinay R. Raj, Owen W. Stephens, Ishwori Dhakal, Shweta S. Chavan, Naveen Sanathkumar, Elizabeth Ann Coleman, Jeannette Y. Lee, Julia A. Goodwin, Senu Apewokin, Daohong Zhou, Joshua Epstein, Christoph J. Heuck, Annette J. Vangsted

Blood (2014) 124 (12): 2001–2003.

https://doi.org/10.1182/blood-2014-07-586701

Published: 2014

Includes: Supplemental data

Journal Articles

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Elizabeth Ann Coleman, PhD, Jeannette Y Lee, Ph.D., Stephen Erickson, Ph.D, Julia Goodwin, PhD, Marjorie Beggs, PhD, Naveen Sanathkumar, MD, Daohong Zhou, MD, Kent McKelvey, MD, Vinay Raj, Ph.D., Senu Apewokin, MD, Owen Stephens, Ph.D., Carol Enderlin, Ph.D., Annette Juul Vangsted, MD, Patty Reed, MS, Elias J. Anaissie, MD

Blood (2013) 122 (21): 3316.

https://doi.org/10.1182/blood.V122.21.3316.3316

Published: 2013

Journal Articles

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Al-Ola Abdallah, MD, Shebli Atrash, MD, Jameel Muzaffar, MD, Nisar Ahmad, MD, Sajjad Haider, MD, Monica Grazziutti, MD, Senu Apewokin, MD, Zainab Shahid, MD, Alejandro Restrepo, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 2925.

https://doi.org/10.1182/blood.V120.21.2925.2925

Published: 2012

Journal Articles

The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis

Xenofon Papanikolaou, MD, Ruslana Tytarenko, Tarun K. Garg, PhD, Sarah K. Johnson, PhD, Erming Tian, Senu Apewokin, MD, Bart Barlogie, MD, Joshua Epstein, DSc, Christoph Heuck, MD

Blood (2012) 120 (21): 4015.

https://doi.org/10.1182/blood.V120.21.4015.4015

Published: 2012

Journal Articles

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Bart Barlogie, MD, PhD, Alan Mitchell, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Monica Grazziutti, MD, Alejandro Restrepo, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Senu Apewokin, MD, Shebli Atrash, MD, Aziz Bakhous, M.D., Sajjad Haider, MD, Surachit Kumar, MD, Jameel Muzaffar, MD, Zainab Shahid, MD, John Crowley, PhD

Blood (2012) 120 (21): 1850.

https://doi.org/10.1182/blood.V120.21.1850.1850

Published: 2012

NARROW

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Email alerts

ASH Publications

American Society of Hematology

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only